Aclaris Therapeutics Appoints Robert Doody as Vice President, Investor Relations
27 September 2022 - 9:00PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced that
it has appointed Robert A. Doody Jr. as Vice President, Investor
Relations.
“We are very excited that we continue further strengthening our
team through the addition of experienced industry veterans with
successful track records,” said Neal Walker, Chief Executive
Officer of Aclaris. “Bob brings to Aclaris considerable experience
leading investor relations programs across a number of various
therapeutic sectors.”
Mr. Doody has nearly 20 years of biotechnology industry
experience leading investor relations programs, most recently
serving as Vice President of Investor Relations at Provention Bio.
Prior to that, Mr. Doody lead investor relations at Idera
Pharmaceuticals, and ViroPharma Incorporated until its acquisition
by Shire Pharmaceuticals.
Prior to joining the industry, Mr. Doody began his career at the
healthcare communications firm, Dorland Sweeney Jones in
Philadelphia, PA. He received his Bachelor of Arts degree in
Communications from Rowan University. Mr. Doody also served
honorably in the United States Navy.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,”
and similar expressions, and are based on Aclaris’ current beliefs
and expectations. These forward-looking statements include the
future contributions of Mr. Doody. These statements involve risks
and uncertainties that could cause actual results to differ
materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially
include uncertainties inherent in the conduct of clinical trials,
Aclaris’ reliance on third parties over which it may not always
have full control, Aclaris’ ability to enter into strategic
partnerships on commercially reasonable terms, the uncertainty
regarding the COVID-19 pandemic and other risks and uncertainties
that are described in the Risk Factors section of Aclaris’ Annual
Report on Form 10-K for the year ended December 31, 2021 and other
filings Aclaris makes with the U.S. Securities and Exchange
Commission from time to time. These documents are available under
the “SEC Filings” page of the “Investors” section of Aclaris’
website at www.aclaristx.com. Any forward-looking statements speak
only as of the date of this press release and are based on
information available to Aclaris as of the date of this release,
and Aclaris assumes no obligation to, and does not intend to,
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024